Centre National De La Recherche Scientifique

Université Claude Bernard Lyon I

Aventis Pharmaceuticals Holdings, Inc.

Merial Limited

Universite Claude Bernard – Lyon1

Societe De Conseils De Recherches Et D'applications Scientifiques (s.c.r.a.s.)

Horus Pharma

Valeant International Bermuda

Université Claude Bernard

Alpol Cosmetique

Hatem Fessi

Francis Puisieux

Jean-Philippe Devissaguet

Franck Gouchet

Elisabeth Laugier-Laglenne

Serge Stainmesse

Martine Claret

Eric Doelker

Denis Labarre

Sandrine Bourgeois

Jérôme Asius

Bénedicte Laglenne

Jean Delaveau

Nada Lambert

Dominique Duchene

Denis Wouessidjewe

Antony Coleman

Mohamed Skiba

Curt Theis

Jean-Phillppe Devissaguet

B&eacute;n&eacute;dicte Laglenne

J&eacute;r&ocirc;me Asius

David Quintanar

Eric Allemann

Marion Dubald

Joseph Lieto

Stephanie Briancon

Imed Montasser

Elisabeth Laugher-Laglenne

Abdelhamid Elaissari

Marie-Alexandrine Bolzinger

Audrey Minost

Lionel Ripoll

Philippe Faure

Sabrina Etheve

Claire Bordes

Catherine Charcosset

The present invention relates to a novel pharmaceutical composition comprising doxycycline for topical application, in particular to the eye and eyelids. The invention also relates to this topical composition for use in the treatment of bacterial infections of the skin and mucous membranes.

Topical doxycycline composition

The present invention relates to novel nanoencapsulated compositions, methods for making such compositions, and methods of repelling insects and other arthropod pests away from animals, including humans. The present invention has particular, though not sole, application to repelling insects including flies and mosquitoes. The inventive compositions may be used to repel arthropods from animals, humans, plants, soil, or building structures. The formulations also prevent illness and disease caused by insect/pest-borne vectors, and provide safer, more effective alternatives to existing repellents.

Long-acting nanoencapsulated coumarin arthropod repellent formulations and methods of use thereof

The invention concerns an injection implant for filling up wrinkles, thin lines, skin cracks and scars, for reparative or plastic surgery, aesthetic dermatology, and for filling up gums in dental treatment. The invention concerns the use of biologically absorbable polymer microspheres or microparticles suspended in a gel. The suspension is produced either ready-for-use or freeze-dried. The biological absorbability of the microspheres is controlled and enables the production of implants having well defined persistence and deliberately limited to 3 years.

Method for subcutaneous or intradermal injection

The invention concerns an injection implant for filling up wrinkles, thin lines, skin cracks and scars, for reparative or plastic surgery, aesthetic dermatology, and for filling up gums in dental treatment. The invention concerns the use of biologically absorbable polymer microspheres or microparticles suspended in a gel. Said suspension is produced either ready-for-use or freeze-dried. The biological absorbability of the microspheres is controlled and enables the production of implants having well defined persistence and deliberately limited to 3 years.

Implant for subcutaneous or intradermal injection

The invention relates to a process for the preparation of dispersible colloidal systems in the form of nanocapsules whose wall consists of a polymer obtained by the polycondensation of two monomers, &#x3b1; and &#x3b2;, and whose core consists of a substance B, characterized in that:

Method for preparing colloidal particles in the form of nanocapsules

A process for the preparation of nanoparticles for the encapsulation of active constituents, the nanocapsules prepared being dispersible in aqueous phase in colloidal form, non-toxic, biocompatible, stable in colloidal suspension and economical. In the process, two non-oily solvents as used, together with a third, oily solvent.

Method for preparing vesicular nanocapsules

A cross-linked copolymer based on at least one non-crosslinked polycarboxylic polysaccharide and at least one second non-crosslinked polycarboxylic polymer which is not a polycarboxylic polysaccharide and a cross-linking agent having at least two amine functions.

Polycarboxylic based cross-linked copolymers

Preparation and use of novel cyclodextrin-based dispersible colloidal

Dispersible colloidal systems of amphiphilic lipids in the form of oligolamellar liposomes of submicron dimensions are prepared by combining a first liquid phase consisting essentially of a solution of the lipids with a greater amount of a second liquid phase consisting essentially of water. The solvent for the first liquid phase is miscible in all proportions with water. If desired, the first liquid phase may also contain a substance A in solution therewith, such as cholesterol. An additional substance B, which is a biologically active substance, may be present in the first phase if it is lipophilic, and in the second phase if it is hydrophilic.

Growing community of inventors

Lyons, France

Hatem Fessi